Bedaquiline patent win is a half victory
Down To Earth| April 16, 2023
India's ability to eliminate its huge TB burden by 2025 will be a test of both its patent laws and healthcare policy
LATHA JISHNU
Bedaquiline patent win is a half victory

THERE WAS a triumphal note as media across the country reported the rejection of Johnson & Johnson's claim for a secondary patent on its tuberculosis drug bedaquiline. It was big news in March when the Indian Patent Office rejected the claim, because bedaquiline is the most efficacious in treating life-threatening cases of drug-resistant TB. It is a medicine that is taken orally, has fewer of the lethal side effects of the older line of drugs and is desperately sought by patients. As a country that is burdened with the largest number of TB cases, and carries an additional load of more than a quarter of the world's drug-resistant cases, India badly needs access to generics medicines that are FEAT inexpensive and available in sufficient quantities. Bedaquiline, a patented medicine made by J&Jowned Janssen Pharmaceuticals, is neither. It is costly and hard to come by.

The original patent on bedaquiline expires in July this year, but J&J had sought to extend its monopoly with a patent for a fumarate salt version of the TB medicine. The claim was opposed in 2019 by two TB patient-activists, Nandita Venkatesan of Mumbai and Phumeza Tisile of South Africa, who were supported by humanitarian organisation Médecins Sans Frontières. The Patent Office upheld their challenge since India's law, specifically Section 3d, does not permit the patenting of incremental improvements on an existing drug unless there is proven improvement in efficacy. The rejection of the secondary patent on bedaquiline means the original patent expiry term stands, allowing generic versions to come into the market in a few months' time. The generic drugs are expected to cut costs as they generally do. J&J charges 27,000 for the prescribed six-month treatment.

There is hope, too, of supplies increasing significantly in the near future as reports talk of some companies launching their generic versions as early as August. 

Esta historia es de la edición April 16, 2023 de Down To Earth.

Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.

Esta historia es de la edición April 16, 2023 de Down To Earth.

Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.

MÁS HISTORIAS DE DOWN TO EARTHVer todo
THE CIRCULARITY ARGUMENT
Down To Earth

THE CIRCULARITY ARGUMENT

A circular economy can help India achieve its developmental aspirations while following the low-carbon pathway. It will also help address the challenges of waste management, pollution and overexploitation of natural resources. Industries are already innovating to reuse high-volume wastes and have shown that the transition can usher in both environmental and financial windfalls

time-read
10+ minutos  |
February 01, 2025
Banking on flawed drug voluntary licences
Down To Earth

Banking on flawed drug voluntary licences

The Medicines Patent Pool is pushing for more VLs, but its bad deal with Novartis on a cancer drug shows the pitfalls

time-read
4 minutos  |
February 01, 2025
Lasting solutions
Down To Earth

Lasting solutions

For the first time, the UN has recognised the role of indigenous communities in tackling aridity. A repository of traditional knowledge India has the wherewithal to lead the way

time-read
3 minutos  |
February 01, 2025
IMD at 150
Down To Earth

IMD at 150

India's journey into modern weather forecasting took a decisive turn 150 years ago with the establishment of India Meteorological Department during the British rule. The agency has come a long way since then, shaping the way the country predicts and responds to its diverse climate challenges

time-read
2 minutos  |
February 01, 2025
Every drop counts
Down To Earth

Every drop counts

In drought-prone Marathwada region, 14 villages have managed to counter water shortage by budgeting the resource

time-read
5 minutos  |
February 01, 2025
Threat to survival
Down To Earth

Threat to survival

Hollongapar Gibbon Sanctuary in Assam faces ecological challenges as railway electrification and hydrocarbon exploration endanger its fragile biodiversity

time-read
5 minutos  |
February 01, 2025
'Migration is going to be a battlefield'
Down To Earth

'Migration is going to be a battlefield'

AMITAV GHOSH is one of the foremost chroniclers of our times. His literary sojourn includes writings on topics that range from languages to climate change to human lives. His latest book, Wild Fictions, brings some of his works on these issues under one title. In a conversation with RAJAT GHAI, Ghosh shares his views on the future of human movement. Excerpts:

time-read
7 minutos  |
February 01, 2025
Face of future
Down To Earth

Face of future

California wildfires confirm forest fires are intensifying in a hotter world, emitting substantial amounts of greenhouse gases and reinforcing global warming

time-read
6 minutos  |
February 01, 2025
Friends of the forest
Down To Earth

Friends of the forest

Residents of 30 villages in Uttarakhand establish a model for public participation in saving forests from wildfires

time-read
2 minutos  |
February 01, 2025
Climate-crazy playbook
Down To Earth

Climate-crazy playbook

Just hours after his second (and final) term began on January 20, US President Donald Trump unleashed 46 presidential actions. Several of these are centred on the US' climate commitments, energy transition, migration and trade policies, and are likely to have negative global implications

time-read
2 minutos  |
February 01, 2025